whitepaper

Article: Defeating COVID-19: The science behind a new ELISA

Posted: 6 April 2021 | | No comments yet

Discover how a new ELISA against S1-RBD for COVID-19 seroconversion detection can accelerate discovery to facilitate vaccine breakthroughs.

The recent and rapid spread of the novel coronavirus, SARS-CoV-2, has necessitated the development of new assays that are capable of detecting the presence of this virus in patient samples or evidence of recent infection. One strategy being developed are assays to detect the presence of anti-SARS-CoV-2 antibodies in patient sera.  Learn how Bethyl’s new ELISAs for COVID-19 seroconversion detection can accelerate discovery through improving the understanding of the virus and immune response to facilitate vaccine breakthroughs and epidemiological studies.












    To read this article in full, please complete the form below:

     










    This specialist content is provided to you free-of-charge thanks to the kind support of Bethyl Laboratories

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend